The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Novel Tools for Production and Purification of Recombinant Adenoassociated Virus Vectors
Abstract
Standard protocols for the generation of adenoassociated virus type 2 (AAV-2)-based vectors for human gene therapy applications require cotransfection of cells with a recombinant AAV (rAAV) vector plasmid and a packaging plasmid that provides the AAV rep and cap genes. The transfected cells must also be overinfected with a helper virus, e.g., adenovirus (Ad), which delivers multiple helper functions necessary for rAAV production. Therefore, rAAV stocks produced using these protocols are contaminated with helper adenovirus. The generation of a novel packaging/helper plasmid, pDG, containing all AAV and Ad functions required for amplification and packaging of AAV vector plasmids, is described here. Cotransfection of cells with pDG and an AAV vector plasmid was sufficient for production of infectious rAAV, resulting in helper virus-free rAAV stocks. The rAAV titers obtained using pDG as packaging plasmid were up to 10-fold higher than those achieved using conventional protocols for rAAV production. Replacement of the AAV-2 p5 promoter by an MMTV-LTR promoter in pDG led to reduced expression of Rep78/68; however, expression of the VP proteins was significantly increased compared with VP levels from standard packaging plasmids. Immunofluorescence analyses showed that the strong accumulation of VP proteins in pDG-transfected cells resulted in enhanced AAV capsid assembly, which is limiting for efficient rAAV production. Furthermore, using a monoclonal antibody highly specific for AAV-2 capsids (A20), an rAAV affinity purification procedure protocol was established. The application of the tools described here led to a significant improvement in recombinant AAV vector production and purification. Two novel tools allowing a simplified and more efficient generation and purification of adenoassociated virus type 2 (AAV-2)-derived vectors are described here. First, the generation of an AAV/adenovirus hybrid plasmid, pDG, which contains all packaging and helper functions required for production of recombinant AAV (rAAV), is reported. Cotransfection of cells with pDG and an AAV vector plasmid led to production of several hundred infectious rAAV particles per transfected cell. Using pDG as a helper plasmid, generation of rAAV was no longer dependent on overinfection of the cells with adenovirus, resulting in helper virus-free rAAV stocks. Second, an rAAV affinity purification procedure based on the monoclonal antibody A20, which specifically recognizes assembled AAV-2 capsids, is described. Detailed analyses of rAAV production using the new packaging and purification tools in comparison with standard protocols are presented.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
High-efficiency transformation of mammalian cells by plasmid DNA.
Chen, C., & Okayama, H. (1987) · Molecular and Cellular Biology · doi:10.1128/mcb.7.8.2745 · Cited by 5,373
Selective extraction of polyoma DNA from infected mouse cell cultures
Hirt, B. (1967) · Journal of Molecular Biology · doi:10.1016/0022-2836(67)90307-5 · Cited by 5,146
Xiao, X., Li, J., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.3.2224-2232.1998 · Cited by 1,381
Kaplitt, M. G., Leone, P., Samulski, R. J., Xiao, X., Pfaff, D. W., O'Malley, K. L., & During, M. J. (1994) · Nature Genetics · doi:10.1038/ng1094-148 · Cited by 1,031
Current Protocols in Human Genetics
(2001) · John Wiley & Sons, Inc. eBooks · doi:10.1002/0471142905 · Cited by 987
Xiao, X., Li, J., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.11.8098-8108.1996 · Cited by 912
Site-specific integration by adeno-associated virus.
Kotin, R. M., Siniscalco, M., Samulski, R. J., Zhu, X. D., Hunter, L., Laughlin, C. A., McLaughlin, S., Muzyczka, N., Rocchi, M., & Berns, K. I. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.6.2211 · Cited by 868
Targeted integration of adeno-associated virus (AAV) into human chromosome 19.
Samulski, R. J., Zhu, X., Xiao, X., Brook, J. D., Housman, D. E., Epstein, N., & Hunter, L. A. (1991) · The EMBO Journal · doi:10.1002/j.1460-2075.1991.tb04964.x · Cited by 784
Ferrari, F. K., Samulski, T., Shenk, T., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.5.3227-3234.1996 · Cited by 761
Samulski, R. J., Chang, L. S., & Shenk, T. (1989) · Journal of Virology · doi:10.1128/jvi.63.9.3822-3828.1989 · Cited by 743
Recombinant adeno-associated virus for muscle directed gene therapy
Fisher, K. J., Jooss, K., Alston, J., Yang, Y., Haecker, S. E., High, K., Pathak, R., Raper, S. E., & Wilson, J. M. (1997) · Nature Medicine · doi:10.1038/nm0397-306 · Cited by 654
Chartier, C., Degryse, E., Gantzer, M., Dieterle, A., Pavirani, A., & Mehtali, M. (1996) · Journal of Virology · doi:10.1128/jvi.70.7.4805-4810.1996 · Cited by 653
Kessler, P. D., Podsakoff, G. M., Chen, X., McQuiston, S. A., Colosi, P. C., Matelis, L. A., Kurtzman, G. J., & Byrne, B. J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.14082 · Cited by 614
A "humanized" green fluorescent protein cDNA adapted for high-level expression in mammalian cells
Zolotukhin, S., Potter, M., Hauswirth, W. W., Guy, J., & Muzyczka, N. (1996) · Journal of Virology · doi:10.1128/jvi.70.7.4646-4654.1996 · Cited by 609
Quantitative analysis of the packaging capacity of recombinant adeno-associated virus
Dong, J.-Y., Fan, P.-D., & Frizzell, R. A. (1996) · Human Gene Therapy · doi:10.1089/hum.1996.7.17-2101 · Cited by 583
Widespread long-term gene transfer to mouse skeletal muscles and heart.
Stratford-Perricaudet, L. D., Makeh, I., Perricaudet, M., & Briand, P. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115902 · Cited by 580
Fisher, K. J., Gao, G. P., Weitzman, M. D., DeMatteo, R., Burda, J. F., & Wilson, J. M. (1996) · Journal of Virology · doi:10.1128/jvi.70.1.520-532.1996 · Cited by 547
McCown, T. J., Xiao, X., Li, J., Breese, G. R., & Jude Samulski, R. (1996) · Brain Research · doi:10.1016/0006-8993(95)01488-8 · Cited by 450
Adeno-associated virus vectors preferentially transduce cells in S phase.
Russell, D. W., Miller, A. D., & Alexander, I. E. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.19.8915 · Cited by 275
Cell Lines for the Production of Recombinant Adeno-Associated Virus
Clark, K. R., Voulgaropoulou, F., Fraley, D. M., & Johnson, P. R. (1995) · Human Gene Therapy · doi:10.1089/hum.1995.6.10-1329 · Cited by 257
Adeno-associated virus Rep proteins target DNA sequences to a unique locus in the human genome
Surosky, R. T., Urabe, M., Godwin, S. G., McQuiston, S. A., Kurtzman, G. J., Ozawa, K., & Natsoulis, G. (1997) · Journal of Virology · doi:10.1128/jvi.71.10.7951-7959.1997 · Cited by 243
Factors Influencing Recombinant Adeno-Associated Virus Production
Salvetti, A., Orève, S., Chadeuf, G., Favre, D., Cherel, Y., Champion-Arnaud, P., David-Ameline, J., & Moullier, P. (1998) · Human Gene Therapy · doi:10.1089/hum.1998.9.5-695 · Cited by 241
Efficient gene transfer into nondividing cells by adeno-associated virus-based vectors
Podsakoff, G., Wong, K. K., & Chatterjee, S. (1994) · Journal of Virology · doi:10.1128/jvi.68.9.5656-5666.1994 · Cited by 231
Role for highly regulated rep gene expression in adeno-associated virus vector production
Li, J., Samulski, R. J., & Xiao, X. (1997) · Journal of Virology · doi:10.1128/jvi.71.7.5236-5243.1997 · Cited by 227
Flotte, T. R., Afione, S. A., & Zeitlin, P. L. (1994) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.11.5.7946381 · Cited by 225
Subcellular compartmentalization of adeno-associated virus type 2 assembly
Wistuba, A., Kern, A., Weger, S., Grimm, D., & Kleinschmidt, J. A. (1997) · Journal of Virology · doi:10.1128/jvi.71.2.1341-1352.1997 · Cited by 219
Self-citationDNA synthesis and topoisomerase inhibitors increase transduction by adeno-associated virus vectors.
Russell, D. W., Alexander, I. E., & Miller, A. D. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5719 · Cited by 218
Snyder, R. O., Spratt, S. K., Lagarde, C., Bohl, D., Kaspar, B., Sloan, B., Cohen, L. K., & Danos, O. (1997) · Human Gene Therapy · doi:10.1089/hum.1997.8.16-1891 · Cited by 211
Adeno-Associated Viruses: An Update
Berns, K. I., & Bohenzky, R. A. (1987) · Advances in Virus Research · doi:10.1016/s0065-3527(08)60479-0 · Cited by 207
Halbert, C. L., Standaert, T. A., Aitken, M. L., Alexander, I. E., Russell, D. W., & Miller, A. D. (1997) · Journal of Virology · doi:10.1128/jvi.71.8.5932-5941.1997 · Cited by 205
Production of Recombinant Adeno‐Associated Viral Vectors
Choi, V. W., Asokan, A., Haberman, R. A., & Samulski, R. J. (2007) · Current Protocols in Human Genetics · doi:10.1002/0471142905.hg1209s53 · Cited by 171
Wistuba, A., Weger, S., Kern, A., & Kleinschmidt, J. A. (1995) · Journal of Virology · doi:10.1128/jvi.69.9.5311-5319.1995 · Cited by 147
Self-citationBalagué, C., Kalla, M., & Zhang, W. (1997) · Journal of Virology · doi:10.1128/jvi.71.4.3299-3306.1997 · Cited by 145
Recruitment of wild-type and recombinant adeno-associated virus into adenovirus replication centers
Weitzman, M. D., Fisher, K. J., & Wilson, J. M. (1996) · Journal of Virology · doi:10.1128/jvi.70.3.1845-1854.1996 · Cited by 142
The adeno-associated virus rep gene suppresses herpes simplex virus-induced DNA amplification
Heilbronn, R., Bürkle, A., Stephan, S., & Hausen, H. Z. (1990) · Journal of Virology · doi:10.1128/jvi.64.6.3012-3018.1990 · Cited by 132
Tamayose, K., Hirai, Y., & Shimada, T. (1996) · Human Gene Therapy · doi:10.1089/hum.1996.7.4-507 · Cited by 132
HSV/AAV Hybrid Amplicon Vectors Extend Transgene Expression in Human Glioma Cells
Johnston, K. M., Jacoby, D. R., Pechan, P. A., Fraefel, C., Borghesani, P. R., Schuback, D. E., Dunn, R. J., Smith, F. I., & Breakefield, X. O. (1997) · Human Gene Therapy · doi:10.1089/hum.1997.8.3-359 · Cited by 131
Lack of Site-Specific Integration of the Recombinant Adeno-Associated Virus 2 Genomes in Human Cells
Ponnazhagan, S., Erikson, D., Kearns, W. G., Zhou, S. Z., Nahreini, P., Wang, X.-S., & Srtvastava, A. (1997) · Human Gene Therapy · doi:10.1089/hum.1997.8.3-275 · Cited by 130
Alexander, I. E., Russell, D. W., Spence, A. M., & Miller, A. D. (1996) · Human Gene Therapy · doi:10.1089/hum.1996.7.7-841 · Cited by 124
Allen, J. M., Debelak, D. J., Reynolds, T. C., & Miller, A. D. (1997) · Journal of Virology · doi:10.1128/jvi.71.9.6816-6822.1997 · Cited by 122
Qing, K., Khuntirat, B., Mah, C. S., Kube, D. M., Wang, X.-S., Ponnazhagan, S., Zhou, S., Dwarki, V., Yöder, M. C., & Srivastava, A. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.1593-1599.1998 · Cited by 119
Conway, J. E., Zolotukhin, S., Muzyczka, N., Hayward, G. S., & Byrne, B. J. (1997) · Journal of Virology · doi:10.1128/jvi.71.11.8780-8789.1997 · Cited by 115
New developments in the generation of Ad-free, high-titer rAAV gene therapy vectors
Ferrari, F. K., Xiao, X., McCarty, D. M., & Samulski, R. J. (1997) · Nature Medicine · doi:10.1038/nm1197-1295 · Cited by 112
Ruffing, M., Zentgraf, H., & Kleinschmidt, J. A. (1992) · Journal of Virology · doi:10.1128/jvi.66.12.6922-6930.1992 · Cited by 109
Self-citationChiorini, J. A., Wendtner, C., Urcelay, E., Safer, B., Hallek, M. J., & Kotin, R. M. (1995) · Human Gene Therapy · doi:10.1089/hum.1995.6.12-1531 · Cited by 107
Latent infection of KB cells with adeno-associated virus type 2
LAUGHLIN, C. A., Cardellichio, C. B., & Coon, H. (1986) · Journal of Virology · doi:10.1128/jvi.60.2.515-524.1986 · Cited by 106
Vincent, K. A., Piraino, S., & Wadsworth, S. C. (1997) · Journal of Virology · doi:10.1128/jvi.71.3.1897-1905.1997 · Cited by 104
Fisher, K. J., Kelley, W. M., Burda, J. F., & Wilson, J. M. (1996) · Human Gene Therapy · doi:10.1089/hum.1996.7.17-2079 · Cited by 93
Malik, P., McQuiston, S. A., Yu, X., Pepper, K. A., Krall, W. J., Podsakoff, G. M., Kurtzman, G. J., & Kohn, D. B. (1997) · Journal of Virology · doi:10.1128/jvi.71.3.1776-1783.1997 · Cited by 83
Myers, M. W., LAUGHLIN, C. A., Jay, F. T., & Carter, B. J. (1980) · Journal of Virology · doi:10.1128/jvi.35.1.65-75.1980 · Cited by 75
Weger, S., Wistuba, A., Grimm, D., & Kleinschmidt, J. A. (1997) · Journal of Virology · doi:10.1128/jvi.71.11.8437-8447.1997 · Cited by 54
Self-citationReplication of rep-cap Genes Is Essential for the High-Efficiency Production of Recombinant AAV
Fan, P., & Dong, J.-Y. (1997) · Human Gene Therapy · doi:10.1089/hum.1997.8.1-87 · Cited by 40
Mamounas, M. J., Leavitt, M., Yu, M., & Wong‐Staal, F. (1995) · PubMed · Cited by 27
Cited by
Zolotukhin, S., Byrne, B. J., Mason, E., Zolotukhin, I., Potter, M., Chesnut, K., Summerford, C., Samulski, R. J., & Muzyczka, N. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300938 · Cited by 1,312
Engineering adeno-associated virus vectors for gene therapy
Li, C., & Samulski, R. J. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-019-0205-4 · Cited by 1,175
Hauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954
Adeno-associated Virus Serotypes: Vector Toolkit for Human Gene Therapy
Wu, Z., Asokan, A., & Samulski, R. J. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.05.009 · Cited by 922
Adeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
Metadata
- Authors
- Grimm, D., Kern, A., Rittner, K., & Kleinschmidt, J. A.
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 1998-12-10
- Volume
- 9
- Issue
- 18
- Pages
- 2745-2760
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W2059108053
- Cited by
- 696
- References
- 53
- FWCI
- 13.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.